Targeted Antigens of CAR-T Cell Therapy Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T35289 | Target Info | |||
Target Name | NKG2 D activating NK receptor (KLRK1) | ||||
Synonyms | NKG2Dactivating NK receptor; NKG2D type II integral membrane protein; NKG2D; NKG2-D-activating NK receptor; NKG2-D type II integral membrane protein; NK cell receptor D; Killer cell lectinlike receptor subfamily K member 1; Killer cell lectin-like receptor subfamily K member 1; D12S2489E; CD314 | ||||
Target Type | Clinical trial Target | ||||
Gene Name | KLRK1 | ||||
UniProt ID |
Targeted Antigens of CAR-T Cell Therapy | Top | ||||
---|---|---|---|---|---|
CAR T-Cell Therapy Drug(s) | CM-CS1 T-cell | Drug Info | Phase 1 | Myelodysplastic syndrome | [1] |
CYAD-101 | Drug Info | Phase 1 | Colorectal cancer | [2] | |
NKR-2 CAR-T Cells | Drug Info | Phase 1 | Myelodysplastic syndrome | [3] | |
NKR-2 cells | Drug Info | Phase 1 | Acute myeloid leukaemia | [4], [5] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT02203825) Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | ||||
REF 2 | ClinicalTrials.gov (NCT03692429) alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells | ||||
REF 3 | ClinicalTrials.gov (NCT03612739) EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 | ||||
REF 4 | ClinicalTrials.gov (NCT03310008) Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases | ||||
REF 5 | ClinicalTrials.gov (NCT03370198) Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.